Dimethylamine

Dimethylamine

SCHEMBL6838255

CCCOCC(Br)c1ccccc1.CNC

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
HTT P42858 1/20 0.36
HTR2A P28223 3/20 0.35
HRH1 P35367 3/20 0.35
ALPL P05186 1/20 0.34
ALPI P09923 1/20 0.34
GAA P10253 1/20 0.34
ALPG P10696 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
SRC P12931 1/20 0.34
SLC6A2 P23975 3/20 0.33
SLC6A4 P31645 3/20 0.33
SLC6A3 Q01959 3/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
KCNH2 Q12809 2/20 0.33
HPGD P15428 1/20 0.33
LMNA P02545 1/20 0.33
TACR1 P25103 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8784173 0.79 HTR2A (0.39) HTR2AHRH1TAAR1CYP2D6TACR1
SCHEMBL7956378 0.77 HSD17B10 (0.41) MAPTHTTHTR2AHRH1HSD17B10
SCHEMBL780668 0.75 HTR2A (0.41) MAPTHTTHTR2AHRH1TAAR1
SCHEMBL22456914 0.74 TAAR1 (0.47) MAPTHSD17B10TAAR1LMNAAOC3
SCHEMBL12064345 0.74 TAAR1 (0.47) MAPTHSD17B10TAAR1LMNAAOC3
SCHEMBL10511898 0.73 LMNA (0.55) MAPTHSD17B10LMNAAOC3
SCHEMBL8041669 0.70 MAPT (0.39) MAPTHTTHTR2AHRH1ALPL
SCHEMBL31304908 0.69 CYP2C19 (0.46) MAPTGAAHSD17B10LMNA
SCHEMBL20995947 0.69 KMT2A (0.50) MAPTLMNA
SCHEMBL687847 0.69 AOC3 (0.46) HTR2AHRH1TAAR1LMNAAOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040049072-A1 RXR modulators with improved pharmacologic profile LIGAND PHARMACEUTICALS INC 2004-03-11 US disclosed
US-6593493-B1 2-(Carboxy(unsaturated)alkyl)-1-(haloalkoxy)benzene derivatives; retinoid X receptors; cardiovascular, skin, eating and vision disorders; anticarcinogenic agents; non-insulin-dependent diabetes LIGAND PHARMACEUTICALS, INC. 2003-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040049072-A1 RXR modulators with improved pharmacologic profile RXRB, RXRG, RXRA MAPT 4169/4885HTT 2931/4885HTR2A 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.